- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ad Stars: McCann HumanCare (Chantix)
FABLE LABEL
agency: McCann Humancare
brand: Chantix
client: Pfizer
photo from left: Doug Welch, SVP, executive creative director • Simon Hunter, SVP, group account director • BJ Kaplan, SVP, executive creative director • John Heath, SVP, group director, strategic planning
Everyone knows the fable about the tortoise and the hare. It was this universal association that made McCann Humancare's print ad for Pfizer's Chantix so effective. By featuring the proverbial race between the turtle and the rabbit, it acknowledged the challenge of quitting smoking and the determination quitters need to stick to treatment—and to battle relapse post-Chantix. The ad didn't need any kind of gimmick, because everyone knows who wins. All McCann had to do was help consumers connect with the mind-set of being determined, steady, and wise.
"In many communications, smokers are vilified and made second-class citizens," explains BJ Kaplan. "Part of this campaign is to praise quitters for the attempts they are taking and to encourage them to quit."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
